These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11123498)

  • 1. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients.
    Kiortsis DN; Giral P; Bruckert E; Turpin G
    J Clin Pharm Ther; 2000 Dec; 25(6):445-51. PubMed ID: 11123498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative therapy use and adherence to antihyperlipidemic drugs in a lipid clinic.
    O'Donnell DC; Brown CM; Piziak VK
    Am J Health Syst Pharm; 2001 Jun; 58(11):1017-21. PubMed ID: 11402475
    [No Abstract]   [Full Text] [Related]  

  • 3. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients.
    Kim YS; Sunwoo S; Lee HR; Lee KM; Park YW; Shin HC; Kim CH; Kim DH; Kim BS; Cha HS; Huh BY;
    Pharmacoepidemiol Drug Saf; 2002; 11(7):593-600. PubMed ID: 12462137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers in utilizing lipid-lowering agents in non-institutionalized population in the U.S.: Application of a theoretical framework.
    Alfaifi AA; Lai L; Althemery AU
    PLoS One; 2021; 16(8):e0255729. PubMed ID: 34352007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, factors influencing and knowledge about adherence to lipid-lowering therapy among hyperlipidemia patients.
    Devaraj NK; Mohamed M; Hussein N
    Med J Malaysia; 2017 Jun; 72(3):157-164. PubMed ID: 28733563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antihypertensive and/or lipid-lowering treatments pattern of compliance in hypertense and/or dyslipemic patients in Primary Care].
    Sicras Mainar A; Fernández de Bobadilla J; Rejas Gutiérrez J; García Vargas M
    An Med Interna; 2006 Aug; 23(8):361-8. PubMed ID: 17067241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usability of the laboratory report and knowledge of lipid-lowering in out-patients from dyslipidemia-related departments].
    Yan SK; Ke YN; Li SS; Jiang H; Li J; Yang H; Wu YF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Dec; 42(6):675-80. PubMed ID: 21170099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of antihyperlipidemic drug management in clinical practice.
    Andrade SE; Saperia GM; Berger ML; Platt R
    Clin Ther; 1999 Nov; 21(11):1973-87. PubMed ID: 10890267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to lipid-lowering drug therapy among members of the Canadian Forces.
    Ma J; Vaillancourt R; Bennett C
    Mil Med; 2008 Jul; 173(7):666-70. PubMed ID: 18700601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to antihyperlipidemic medication and lipid control in diabetic Veterans Affairs patients with psychotic disorders.
    Nelson LA; Graham MR; Lindsey CC; Rasu RS
    Psychosomatics; 2011; 52(4):310-8. PubMed ID: 21777713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
    Kiortsis DN; Elisaf MS
    Fundam Clin Pharmacol; 2001 Dec; 15(6):401-3. PubMed ID: 11860528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using lipid-lowering agents effectively. When diet is not enough.
    Scott D; Kurenitz M
    Postgrad Med; 1990 Jun; 87(8):171-6, 179-81, 186. PubMed ID: 2189126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education].
    Márquez Contreras E; Casado Martínez JJ; López de Andrés M; Corés Prieto E; López Zamorano JM; Moreno García JP; Martín de Pablos JL; Marín Fernández J
    Aten Primaria; 1998 Jun; 22(2):79-84. PubMed ID: 9717348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid disorders: justification of methods and goals of treatment.
    Braunstein JB; Cheng A; Cohn G; Aggarwal M; Nass CM; Blumenthal RS
    Chest; 2001 Sep; 120(3):979-88. PubMed ID: 11555537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adherence to antihypertensive and lipid-lowering medications: a problem of public health, not yet resolved].
    Grosso G; Raciti T; Marventano S; Romeo I; Mistretta A
    Ann Ig; 2011; 23(2):173-84. PubMed ID: 21770233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of coronary heart disease risk management in high-risk patients.
    Leitha T; Staudenherz A; Bachmann B; Dudczak R
    Clin Cardiol; 1994 Mar; 17(3):123-30. PubMed ID: 8168280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
    Pearson TA; Laurora I; Chu H; Kafonek S
    Arch Intern Med; 2000 Feb; 160(4):459-67. PubMed ID: 10695686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.